Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial

Medicine & Life Sciences

• emtricitabine tenofovir alafenamide 100%
• Cobicistat 92%
• Darunavir 80%
• Emtricitabine 76%
• Equivalence Trials 71%
• Tenofovir 68%
• Protease Inhibitors 55%
• Tablets 49%
• HIV-1 46%
• Safety 31%
• Viral Load 15%
• GS-7340 7%
• Control Groups 6%
• North America 4%
• Random Allocation 4%
• Pancreatitis 4%
• Intention 3%
• HDL Cholesterol 3%
• HIV Infections 3%
• Multicenter Studies 3%
• Cholesterol 3%
• HIV 2%
• Pharmaceutical Preparations 1%
• Population 1%
• Therapeutics 1%